These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23844703)

  • 1. The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.
    Lu Z; Rynkiewicz MJ; Yang CY; Madico G; Perkins HM; Wang Q; Costello CE; Zaia J; Seaton BA; Sharon J
    Immunology; 2013 Nov; 140(3):374-89. PubMed ID: 23844703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.
    Lu Z; Madico G; Roche MI; Wang Q; Hui JH; Perkins HM; Zaia J; Costello CE; Sharon J
    Immunology; 2012 Jul; 136(3):352-60. PubMed ID: 22486311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.
    Lu Z; Perkins HM; Sharon J
    Clin Vaccine Immunol; 2014 Feb; 21(2):227-33. PubMed ID: 24351753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.
    Lu Z; Rynkiewicz MJ; Yang CY; Madico G; Perkins HM; Roche MI; Seaton BA; Sharon J
    Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):235-45. PubMed ID: 25171003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.
    Roche MI; Lu Z; Hui JH; Sharon J
    Hybridoma (Larchmt); 2011 Feb; 30(1):19-28. PubMed ID: 21466282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell epitopes in GroEL of Francisella tularensis.
    Lu Z; Rynkiewicz MJ; Madico G; Li S; Yang CY; Perkins HM; Sompuram SR; Kodela V; Liu T; Morris T; Wang D; Roche MI; Seaton BA; Sharon J
    PLoS One; 2014; 9(6):e99847. PubMed ID: 24968190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies to
    Stefanetti G; Okan N; Fink A; Gardner E; Kasper DL
    Proc Natl Acad Sci U S A; 2019 Apr; 116(14):7062-7070. PubMed ID: 30872471
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.
    Rynkiewicz MJ; Lu Z; Hui JH; Sharon J; Seaton BA
    Biochemistry; 2012 Jul; 51(28):5684-94. PubMed ID: 22747335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.
    Wang Q; Shi X; Leymarie N; Madico G; Sharon J; Costello CE; Zaia J
    Biochemistry; 2011 Dec; 50(50):10941-50. PubMed ID: 22091710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.
    Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J
    Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
    Hickey AJ; Hazlett KR; Kirimanjeswara GS; Metzger DW
    Vaccine; 2011 Sep; 29(40):6941-7. PubMed ID: 21803089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].
    Pavlovich NV; Aronova NV; Onoprienko NN; Sorokin VM; Mazrukho BL
    Mol Gen Mikrobiol Virusol; 2000; (3):7-12. PubMed ID: 10975073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-adaptation of Francisella tularensis alters the bacterium's surface-carbohydrates to hinder effectors of innate and adaptive immunity.
    Zarrella TM; Singh A; Bitsaktsis C; Rahman T; Sahay B; Feustel PJ; Gosselin EJ; Sellati TJ; Hazlett KR
    PLoS One; 2011; 6(7):e22335. PubMed ID: 21799828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.
    Chen L; Valentine JL; Huang CJ; Endicott CE; Moeller TD; Rasmussen JA; Fletcher JR; Boll JM; Rosenthal JA; Dobruchowska J; Wang Z; Heiss C; Azadi P; Putnam D; Trent MS; Jones BD; DeLisa MP
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3609-18. PubMed ID: 27274048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The preventive activity of monoclonal antibodies specific to the lipopolysaccharide of Francisella tularensis].
    Khlebnikov VS; Vetchinin SS; Grechko GK; Averina AA; Golovlev IR; Averin SF; Zhemchugov VE; Konovalov SI; Anisimov GA; Afanas'ev SS
    Zh Mikrobiol Epidemiol Immunobiol; 1992; (9-10):67-70. PubMed ID: 1481610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.
    Apicella MA; Post DM; Fowler AC; Jones BD; Rasmussen JA; Hunt JR; Imagawa S; Choudhury B; Inzana TJ; Maier TM; Frank DW; Zahrt TC; Chaloner K; Jennings MP; McLendon MK; Gibson BW
    PLoS One; 2010 Jul; 5(7):e11060. PubMed ID: 20625403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin G subclass switching impacts sensitivity of an immunoassay targeting Francisella tularensis lipopolysaccharide.
    Nualnoi T; Kirosingh A; Basallo K; Hau D; Gates-Hollingsworth MA; Thorkildson P; Crump RB; Reed DE; Pandit S; AuCoin DP
    PLoS One; 2018; 13(4):e0195308. PubMed ID: 29630613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
    Mahawar M; Rabadi SM; Banik S; Catlett SV; Metzger DW; Malik M; Bakshi CS
    PLoS One; 2013; 8(4):e61539. PubMed ID: 23613871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
    Jia Q; Lee BY; Bowen R; Dillon BJ; Som SM; Horwitz MA
    Infect Immun; 2010 Oct; 78(10):4341-55. PubMed ID: 20643859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
    Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
    J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.